Anthony Fauci
Anthony S. Fauci (born December 24, 1940) is an American physician and immunologist who directed the National Institute of Allergy and Infectious Diseases (NIAID) from 1984 to 2022 and served as Chief Medical Advisor to the President from January 2021 to December 2022.[1][2][3] Fauci's career focused on infectious diseases, including early research on HIV/AIDS where he contributed to understanding immune responses and advancing antiretroviral therapies, later advising on the President's Emergency Plan for AIDS Relief (PEPFAR), which has supported treatment for millions globally.[4][5] He also guided U.S. responses to outbreaks like Ebola and Zika, emphasizing vaccine development and public health strategies through NIAID's research portfolio.[2] During the COVID-19 pandemic, Fauci became a prominent public figure advocating masking, social distancing, and vaccination, but faced scrutiny over NIAID's funding of bat coronavirus research at the Wuhan Institute of Virology via EcoHealth Alliance grants, which critics argued constituted gain-of-function experiments enhancing viral transmissibility despite Fauci's congressional testimony denying such classification under federal definitions.[6][7] House investigations highlighted discrepancies in his statements on research risks and the pandemic's origins, with genomic analyses and subcommittee findings supporting plausibility of a lab leak over natural zoonosis, amid broader debates on transparency in federal funding oversight.[8][9][10]
Early Life and Education
Family Background and Childhood
Anthony Stephen Fauci was born on December 24, 1940, in Brooklyn, New York, to Stephen A. Fauci and Eugenia Lillian (née Abys) Fauci, both first-generation Italian Americans whose families originated from southern Italy, including maternal grandparents from the Naples region.[1][11] His father, who graduated from Columbia University's College of Pharmacy, owned and operated Fauci Pharmacy in the Dyker Heights neighborhood of Brooklyn, where the family resided above the store after relocating there during Fauci's elementary school years.[12][13] Fauci's mother had attended Hunter College, and the couple raised two children, with Fauci as the younger sibling to an older sister.[1] Raised in a Catholic household, Fauci received his first Communion at age seven and was confirmed at twelve, attending elementary school at Our Lady of Guadalupe in Brooklyn's Bensonhurst neighborhood before the family's move.[14] From a young age, he assisted his father in the family pharmacy by delivering prescriptions and other items to customers, an experience that instilled early discipline and familiarity with pharmaceuticals.[11] The family's emphasis on education and hard work, rooted in their immigrant heritage, shaped Fauci's formative years in the working-class Italian-American community of mid-20th-century Brooklyn.[12]Academic and Medical Training
Fauci attended the College of the Holy Cross in Worcester, Massachusetts, graduating in 1962 with a Bachelor of Arts degree focused on pre-medicine.[3] He subsequently enrolled at Cornell University Medical College in New York City, receiving his Doctor of Medicine degree in 1966.[15] After medical school, Fauci completed an internship and residency in internal medicine at New York Hospital-Cornell Medical Center, now part of NewYork-Presbyterian/Weill Cornell Medical Center.[15] In 1968, he entered the National Institutes of Health through the U.S. Public Health Service, serving as a clinical associate in the Laboratory of Clinical Investigation at the National Institute of Allergy and Infectious Diseases.[15] [3] During his time at the NIH, Fauci undertook fellowship training in infectious diseases, focusing on clinical research in immunology and related fields.[16] This period marked his transition from general medical training to specialized expertise in infectious disease pathogenesis and host immune responses.[17]Professional Career at NIH and NIAID
Appointment to Key Positions
Anthony Fauci joined the National Institutes of Health (NIH) in 1968 as a clinical associate in the Laboratory of Clinical Investigation at the National Institute of Allergy and Infectious Diseases (NIAID).[15][18] In the early 1970s, he advanced to head the Clinical Physiology Section within that laboratory.[15] By January 1977, Fauci had been promoted to deputy clinical director of NIAID.[3] In 1980, Fauci was appointed chief of NIAID's Laboratory of Immunoregulation, a new unit focused on immune system regulation research.[1] This role positioned him at the forefront of emerging infectious disease studies amid the initial reports of AIDS cases.[1] Four years later, in 1984, NIH Director James B. Wyngaarden selected Fauci to serve as the fifth director of NIAID.[1] He retained this leadership position for 38 years, overseeing NIAID's expansion into major global health threats until his retirement on December 31, 2022.[2][19]
Research in Immunology and Infectious Diseases
Fauci joined the National Institutes of Health (NIH) in 1968 as a clinical associate in the Laboratory of Clinical Investigation at the National Institute of Allergy and Infectious Diseases (NIAID).[15] His early research focused on the pathogenesis and treatment of immune-mediated inflammatory diseases, particularly systemic vasculitides.[20] In collaboration with Sheldon M. Wolff, he conducted clinical studies demonstrating that combination therapy with cyclophosphamide and prednisone could achieve sustained remissions in patients with severe Wegener's granulomatosis (now known as granulomatosis with polyangiitis), a previously often-fatal condition characterized by necrotizing granulomatous inflammation of the respiratory tract and systemic vasculitis.[21] [22] A 1973 study reviewed 18 patients, showing that this regimen induced remissions in 16 cases, with follow-up data indicating durable responses even after dose reduction.[21] A prospective trial published in 1983 further confirmed long-term remission rates exceeding 90% in active disease, transforming management of this and related vasculitides like polyarteritis nodosa and lymphomatoid granulomatosis from supportive care to targeted immunosuppression.[23] [24] Fauci's work extended to elucidating mechanisms of immune dysregulation in these conditions, including the effects of cyclophosphamide on lymphocyte subpopulations, which produced profound and prolonged lymphocytopenia while preserving clinical efficacy.[25] These findings established immunosuppressive protocols that reduced mortality from near 100% to treatable levels, influencing subsequent guidelines for vasculitis management.[26] By the early 1980s, Fauci had authored over 100 scientific papers and chapters on immunology, contributing to foundational understanding of T-cell function and suppressor mechanisms in immune homeostasis.[16] In parallel, Fauci advanced research on cytokine-mediated immune regulation, delineating roles of interleukins such as IL-2 in modulating T-cell proliferation and activation, which informed broader applications in immunotherapy for immune-mediated and infectious pathologies.[20] As chief of the Laboratory of Immunoregulation, his group investigated how dysregulated cytokine signaling contributes to aberrant immune responses, laying groundwork for therapeutic modulation independent of specific pathogens.[27] These efforts, spanning basic and translational immunology, positioned Fauci as a highly cited researcher, ranking ninth among 3.3 million authors in immunology by citation count from 1980 to 2022.[20] His pre-1984 output emphasized clinical translation, bridging empirical observations from patient cohorts to mechanistic insights into immune tolerance and inflammation.[28]Responses to Pre-COVID Public Health Crises
HIV/AIDS Epidemic
Anthony Fauci admitted his first AIDS patient to the NIH Clinical Center in January 1982, early in the recognition of the emerging epidemic, which had been first reported by the CDC in June 1981 with cases of Pneumocystis pneumonia among gay men in Los Angeles.[29] As chief of the Laboratory of Immunoregulation at NIAID since 1980, Fauci shifted focus to studying the immunopathogenesis of HIV, elucidating how the virus depleted CD4 T cells and led to opportunistic infections.[30] He was appointed director of NIAID on November 2, 1984, overseeing an expanding portfolio that included directing federal research efforts against the virus amid rising case numbers, with over 15,000 reported AIDS cases and more than 8,000 deaths in the U.S. by mid-1985.[31][32] Fauci's leadership faced intense scrutiny from AIDS activists, particularly ACT UP, who protested NIH policies for bureaucratic delays in drug testing and exclusion of patients from trials.[33] In December 1988, activists stormed NIH buildings, targeting Fauci personally and chanting slogans accusing him of complicity in deaths due to slow approvals.[34] Responding to demands, Fauci advocated for the parallel track mechanism in 1989, allowing expanded access to experimental therapies outside formal trials for those ineligible for standard protocols, which expedited treatments like ddI.[35] He also facilitated activist inclusion on advisory committees, marking a shift from confrontation to collaboration, though tensions persisted with figures like Larry Kramer, who initially labeled Fauci a "murderer" but later acknowledged his efforts.[36][37] Under Fauci's direction, NIAID supported pivotal developments, including the 1987 FDA accelerated approval of zidovudine (AZT), the first antiretroviral, based on a trial showing delayed disease progression in 282 participants, though high doses later revealed toxicity concerns prompting dosage reductions.[38] Critics, including some activists and later figures like Robert F. Kennedy Jr., alleged over-reliance on AZT and suppression of alternatives, claiming it caused more harm than good, but epidemiological data indicate it extended survival for many before combination therapies emerged in the mid-1990s.[39][40] Fauci's tenure saw NIAID allocate billions to HIV research, contributing to the identification of HIV as the causative agent in 1984 and foundational work on vaccines and antiretrovirals that reduced U.S. AIDS deaths from 50,000 in 1995 to under 20,000 by 1997.[41] These advances, while not eradicating the virus, transformed HIV from a near-uniformly fatal diagnosis to a manageable chronic condition for those with access to care.[42]2009 H1N1 Swine Flu Pandemic
As director of the National Institute of Allergy and Infectious Diseases (NIAID), Anthony Fauci directed the agency's scientific efforts during the 2009 H1N1 influenza pandemic, which began with initial cases reported in Mexico and the United States in late April 2009. NIAID leveraged its established influenza research infrastructure, including the Centers of Excellence for Influenza Research and Surveillance (CEIRS), to rapidly characterize the novel swine-origin virus and monitor its evolution in animal models, such as ferrets, where it demonstrated capacity to cause more severe disease than typical seasonal strains. Fauci emphasized in congressional testimony that this pre-existing platform enabled a swift response, including identification of vaccine strains within months of the outbreak's emergence.[43][43] NIAID supported accelerated development of both inactivated and live attenuated vaccines in collaboration with industry partners, culminating in FDA approval by September 2009 and initial lots available in early October 2009. Clinical trials conducted through NIAID's Vaccine and Treatment Evaluation Units, initiated in August 2009, yielded preliminary data on September 11, 2009, indicating that a single 15-microgram dose was safe and immunogenic in adults aged 18-64, producing protective antibody responses. Ongoing trials assessed dosing in children, pregnant women, the elderly, and high-risk groups, with results expected by late October 2009; separate studies evaluated co-administration with seasonal influenza vaccines and explored adjuvanted formulations to enhance supply efficiency. Fauci also oversaw research into diagnostics, including point-of-care platforms for rapid virus detection, and therapeutics, such as testing the efficacy of antivirals like oseltamivir against the new strain while advancing next-generation candidates.[43][43][43] In public communications, Fauci testified before the House Committee on Oversight and Government Reform on September 29, 2009, detailing these NIH-supported advancements and underscoring the need for continued surveillance to track viral mutations, which had not significantly altered the strain's antigenicity by that point. He described the pandemic as highly transmissible person-to-person but of mild to moderate severity overall, with approximately 70% of fatalities occurring in individuals with underlying conditions and the remainder in previously healthy people due to inherent biological variability in immune responses. Fauci promoted vaccination as a core countermeasure, asserting in media interviews that the H1N1 vaccine—produced via the same methods as seasonal influenza vaccines—demonstrated safety in trials involving millions, elicited immune responses in over 90% of pregnant women tested, and required only a single dose for adequate protection in most adults, countering public hesitancy by highlighting its established manufacturing process and clinical data.[43][44][45]Ebola Outbreak and Congressional Testimony
In response to the 2014 Ebola virus disease outbreak in West Africa, which originated in Guinea in December 2013 and escalated into the largest recorded Ebola epidemic with 28,616 confirmed, probable, and suspected cases and 11,310 deaths by its conclusion in June 2016, Anthony Fauci directed NIAID's contributions to U.S. and international efforts. NIAID, under Fauci's leadership, accelerated research into vaccines such as the rVSV-ZEBOV candidate, monoclonal antibody therapies like ZMapp, and diagnostics, collaborating with partners including the Biomedical Advanced Research and Development Authority (BARDA) to fast-track clinical trials.[46] Fauci emphasized that containment in West Africa was critical to prevent secondary outbreaks elsewhere, warning that unchecked spread could lead to over 1 million cases by early 2015 without global mobilization.[47] The outbreak reached the United States with the importation of the first case, Liberian national Thomas Eric Duncan, who flew into Dallas on September 25, 2014, and sought care at Texas Health Presbyterian Hospital on September 28 before being diagnosed with Ebola on September 30; Duncan died on October 8 despite receiving experimental treatment with brincidofovir.[48] Two nurses at the hospital, Nina Pham and Amber Vinson, subsequently contracted Ebola—Pham confirmed positive on October 12 and Vinson on October 15—marking the first known secondary transmissions in the U.S.; both recovered after receiving supportive care and the experimental Zmapp antibody cocktail, with Pham discharged on October 24.[48] [49] Fauci publicly asserted that Ebola transmission required direct contact with bodily fluids of symptomatic individuals and was not airborne, attributing U.S. infections to lapses in personal protective equipment (PPE) protocols and training at the Dallas facility rather than inherent uncontrollability of the virus in advanced healthcare settings.[50] He maintained that the U.S. risk of sustained community spread remained low due to superior surveillance, isolation capabilities, and contact tracing compared to West Africa.[46] Fauci testified on October 16, 2014, before the House Energy and Commerce Subcommittee on Oversight and Investigations during a hearing titled "Examining the U.S. Public Health Response to the Ebola Outbreak," alongside CDC Director Tom Frieden and other officials.[51] In his prepared statement, Fauci detailed NIAID's role in funding and overseeing Ebola research since the 1980s, including surge capacity for experimental therapeutics, and urged Congress to support increased funding for biodefense preparedness to address gaps exposed by the crisis, such as limited domestic manufacturing of PPE and therapeutics.[46] Lawmakers, including Republicans, pressed Fauci and witnesses on accountability for the Dallas infections, questioning why initial protocols failed despite federal guidance and whether assurances of low risk underestimated healthcare worker vulnerabilities; Fauci responded that while the science of transmission was well-established, implementation errors at the local level—such as improper doffing of PPE—highlighted the need for rigorous simulation training and standardized procedures, without conceding systemic federal shortcomings.[52] 61906-1/fulltext) The hearing underscored tensions over travel restrictions from affected countries, with Fauci aligning with administration policy against broad bans, arguing they could hinder containment efforts in origin zones.[53]Role in the COVID-19 Pandemic
Under the Trump Administration
On January 29, 2020, President Donald Trump established the White House Coronavirus Task Force to monitor, contain, and mitigate the spread of COVID-19, with Anthony Fauci appointed as a key member alongside Vice President Mike Pence, Secretary of Health and Human Services Alex Azar, and others.[54][55] As director of the National Institute of Allergy and Infectious Diseases (NIAID), Fauci served as the chief scientific advisor, providing daily updates on the virus's epidemiology, testing strategies, and potential treatments during task force meetings.[56] Fauci participated in numerous White House press briefings starting in late February 2020, where he explained the scientific rationale for measures like travel restrictions from China on January 31, 2020, and the eventual declaration of a national emergency on March 13, 2020.[57] He emphasized the virus's potential for widespread transmission, projecting in early March that up to 75-80% of the U.S. population could eventually be infected without interventions, while advocating for social distancing and school closures to flatten the curve.[58] These briefings often featured Fauci alongside Trump, highlighting alignments on accelerating vaccine development through public-private partnerships. Fauci contributed to Operation Warp Speed, the Trump administration's initiative launched in May 2020 to expedite COVID-19 vaccines, which involved over $10 billion in federal funding for candidates like those from Moderna and Pfizer-BioNTech.[59] He later credited the program for enabling vaccine availability by December 2020, receiving a Presidential Commendation from Trump on January 19, 2021, for his role in the effort.[60] Fauci also advised on therapeutic options, cautioning against unproven treatments like hydroxychloroquine despite initial emergency use authorization on March 28, 2020, which was revoked by June 15, 2020, following clinical trial data showing limited efficacy and potential risks.[55] Public health guidance under Fauci's influence evolved significantly; in early March 2020, he stated masks were not necessary for the general public to prevent infection, prioritizing supplies for healthcare workers amid shortages.[61] By April 3, 2020, following emerging evidence of asymptomatic transmission, the CDC—aligned with Fauci's task force input—recommended voluntary cloth face coverings in public settings, a shift Fauci attributed to new data indicating 40-45% of transmissions from asymptomatic carriers.[62][63] This change occurred amid internal debates, with Trump declining to wear a mask personally while endorsing the guidance for others.[64] Tensions surfaced publicly between Fauci and Trump, particularly after Trump's April 23, 2020, remarks suggesting possible disinfectant or light-based treatments, which Fauci clarified did not reflect scientific consensus during subsequent briefings.[58] Fauci maintained that under-the-curve suppression strategies, including lockdowns, were essential to avoid overwhelming hospitals, diverging from Trump's push for economic reopening by May 2020.[55] Despite frictions, Fauci continued advising through the administration's end, focusing on scaling testing to over 1 million daily by late 2020 and preparing for vaccine distribution.[65]Under the Biden Administration
On January 20, 2021, President Joe Biden appointed Anthony Fauci as Chief Medical Advisor to the President, a newly created position focused on COVID-19 response, while Fauci retained his role as director of the National Institute of Allergy and Infectious Diseases (NIAID).[66] [67] Fauci also served as a key member of the White House COVID-19 Response Team, advising on strategies to accelerate vaccination, enhance testing, and address variants.[66] Fauci advocated for policies emphasizing vaccination coverage, including support for booster shots amid emerging data on waning immunity and new variants like Delta and Omicron. In September 2021, he endorsed mandates for large employers and federal workers, aligning with Biden's announcement requiring vaccination or testing for over 100 million Americans.[68] [69] He publicly supported COVID-19 vaccine requirements for domestic air travel in September and December 2021, arguing they would reduce transmission risks based on observational data from vaccinated populations.[70] [71] Fauci pushed for booster authorization even prior to full FDA endorsement, citing preliminary Israeli and U.S. studies showing restored protection against infection, though later empirical evidence indicated limited impact on transmission.[72] Fauci testified before Congress multiple times on the pandemic response, including on NIH budget requests on May 25, 2021; COVID-19 variants and vaccines on July 20 and November 4, 2021; and Omicron impacts on January 11, 2022.[73] [74] [75] [76] During these appearances, he addressed federal funding for research, vaccine efficacy against hospitalization (estimated at over 90% for severe outcomes per CDC data), and the need for layered interventions despite criticisms of over-reliance on non-pharmaceutical measures amid high vaccination rates.[77] On August 22, 2022, Fauci announced his intention to step down from both positions by December 31, 2022, after over 50 years of federal service, citing a desire to pursue private endeavors while praising the Biden administration's extension of his advisory role.[67] [78] As Biden's term ended, on January 20, 2025, the president issued a preemptive pardon to Fauci for any potential federal offenses related to his pandemic tenure, a move Fauci acknowledged appreciatively but stated was unnecessary as he had committed no crimes.[79] [80] Trump and Republican critics challenged the pardons' validity, alleging autopen use amid questions about Biden's capacity rendered them ineffective.[81] This action underscored persistent partisan divides over accountability for public health decisions, with empirical reviews later questioning aspects of guidance efficacy against community spread.[82]Major Controversies
Gain-of-Function Research and Funding
As director of the National Institute of Allergy and Infectious Diseases (NIAID) from 1984 to 2022, Anthony Fauci oversaw the agency's grant-making process, including funding for research on bat coronaviruses conducted in collaboration with the Wuhan Institute of Virology (WIV). In 2014, NIAID awarded a five-year grant totaling $3.75 million to EcoHealth Alliance under grant number R01AI110964 to study the emergence risks of bat-borne coronaviruses in China, with approximately $600,000 subawarded to the WIV for sample collection and virus characterization.[83][84] This funding supported experiments involving the creation of chimeric viruses by inserting spike proteins from naturally occurring bat coronaviruses into a mouse-adapted SARS-like backbone, which unexpectedly enhanced the viruses' ability to infect and sicken engineered mice.[85][86] The research fell under the category of gain-of-function (GOF) studies, which involve modifying pathogens to confer new or enhanced traits, such as increased transmissibility or pathogenicity, to assess pandemic risks. A 2015 progress report from EcoHealth detailed WIV experiments where chimeric viruses replicated better than the parental strain in humanized mouse lungs and caused more severe disease, triggering a requirement under grant terms to report such enhancements within specified thresholds; however, EcoHealth did not promptly notify NIAID, leading to a 2021 NIH determination of noncompliance.[85][87] Fauci had previously co-authored a 2011 paper warning of GOF risks, contributing to a 2014 U.S. funding moratorium on certain influenza, SARS, and MERS GOF research, which paused aspects of the EcoHealth grant until 2017.[84] Post-moratorium, the U.S. government adopted the Potential Pandemic Pathogen Care and Oversight (P3CO) framework, defining GOF research of concern as that reasonably anticipated to create enhanced potential pandemic pathogens (ePPPs).[88][89] During 2021 Senate hearings, Fauci testified that NIAID "has not ever and does not now fund gain-of-function research in the Wuhan Institute of Virology," asserting the funded work did not meet the P3CO definition because enhancements were unanticipated and fell below reporting thresholds.[84][90] Critics, including Senator Rand Paul, contended this relied on a narrow regulatory definition excluding broader GOF practices like serial passaging or receptor-binding enhancements, and accused Fauci of misleading Congress given internal NIAID emails acknowledging the research's proximity to GOF.[84][6] In a 2024 House Oversight Committee hearing, NIH Principal Deputy Director Lawrence Tabak testified that the agency did fund GOF research at WIV via EcoHealth, contradicting Fauci's prior statements, while a Republican-led subcommittee report labeled Fauci's testimony "untruthful."[91][6] The grant was renewed in 2019 but suspended in 2020 amid origins scrutiny, terminated in 2022, and partially restarted in 2023 without WIV subawards following further reviews.[92][93]| Key Grant Details (R01AI110964) | Description |
|---|---|
| Award Date | June 2014 (initial five-year period)[83] |
| Total NIAID Funding to EcoHealth | $3.75 million over five years[83] |
| Subaward to WIV | ~$600,000 for bat sampling and virus studies[84] |
| Experiments Funded | Chimeric virus construction; serial passaging in cells and mice, yielding enhanced lung infection[85] |
| Reporting Issue | 2021 NIH finding of untimely disclosure of enhanced pathogenicity[85] |
COVID-19 Origins and Lab Leak Hypothesis
In January and February 2020, Anthony Fauci, as director of the National Institute of Allergy and Infectious Diseases (NIAID), received communications from virologists expressing concerns about features of SARS-CoV-2 suggestive of laboratory engineering. On January 31, 2020, virologist Kristian G. Andersen emailed Fauci stating that the virus's genome had unusual characteristics that "look engineered," and other scientists similarly raised alarms about potential manipulation.[95] On February 1, 2020, Fauci participated in a conference call with National Institutes of Health (NIH) Director Francis Collins and more than eleven scientists, during which participants discussed evidence pointing to a possible lab leak from the Wuhan Institute of Virology (WIV) and genetic alterations.[96] Following these discussions, Fauci and Collins engaged with scientists who drafted the "Proximal Origin of SARS-CoV-2" paper, published in Nature Medicine on March 17, 2020, which argued that the virus had a natural zoonotic origin and dismissed laboratory manipulation as implausible. Emails indicate that Andersen and co-authors, prompted by Fauci, Collins, and Wellcome Trust Director Jeremy Farrar, focused efforts on disproving a lab origin, with drafts shared for review and editing by Fauci and Collins before submission.[96] On April 17, 2020, Fauci publicly cited this paper during a White House briefing to reject the lab leak hypothesis as a conspiracy theory lacking scientific basis.[97] Collins later emailed Fauci on April 16, 2020, inquiring whether NIH could help "put down" the lab leak idea, reflecting coordinated efforts to shape the narrative toward natural spillover.[96] Fauci's agency had funded research at WIV through grants to EcoHealth Alliance, including $3.7 million from 2014 to 2019 for studying bat coronaviruses, some of which involved creating chimeric viruses by inserting spike proteins from naturally occurring bat viruses into backbones of other coronaviruses. In 2018–2019 experiments, WIV researchers modified a bat coronavirus (SHC014 WIV1) that unexpectedly increased pathogenicity in humanized mice by more than the required threshold for reporting enhanced potential pandemic pathogens, but EcoHealth failed to promptly notify NIH as stipulated in grant terms.[85] Critics, including biosafety expert Richard Ebright, argue this constituted gain-of-function (GoF) research—defined under the 2014 U.S. moratorium as experiments enhancing transmissibility or virulence—despite Fauci's repeated denials that NIH funded such work at WIV.[85] In May 2021 congressional testimony, Fauci maintained that the funded experiments did not meet the GoF definition, a position contradicted in 2024 by NIH Acting Director Lawrence Tabak, who confirmed NIH supported GoF research in Wuhan via EcoHealth.[91] The lab leak hypothesis posits that SARS-CoV-2 escaped from WIV, which conducted GoF-like experiments on bat coronaviruses closely related to SARS-CoV-2 (e.g., RaTG13, sharing 96% genetic similarity), amid reports of researcher illnesses in late 2019 and documented biosafety lapses at the lab.[98] The U.S. Intelligence Community's 2021 declassified assessment found no consensus: four agencies favored natural exposure (low confidence), one assessed a lab-associated incident (moderate confidence), and three were undecided, citing insufficient data and China's non-cooperation.[98] A December 2024 House Select Subcommittee report, after reviewing over 30 interviews and documents, concluded the pandemic likely stemmed from a WIV lab leak, criticizing Fauci's early dismissal of the theory as premature and influenced by conflicts of interest among scientists with WIV ties.[9] In June 2024 testimony before the House Select Subcommittee on the Coronavirus Pandemic, Fauci denied orchestrating a cover-up, affirmed an "open mind" on lab leak origins, and reiterated that it was not inherently conspiratorial, though he acknowledged prompting the Proximal Origin paper to address early concerns.[8] He maintained NIH did not fund GoF at WIV but admitted bulk-signing grants without detailed review and agreed that EcoHealth President Peter Daszak, who coordinated with WIV, should be barred from future U.S. funding due to misconduct.[8] These positions evolved from his initial public skepticism, amid ongoing debates over whether early suppression of lab leak discussions—potentially driven by institutional ties to funded research—delayed impartial investigation.[99]Evolving Public Health Guidance
During the COVID-19 pandemic, Anthony Fauci's public health recommendations underwent several notable shifts, prompting criticism for perceived inconsistencies that undermined public confidence. These changes, often attributed to emerging scientific evidence, included initial discouragement of widespread mask use followed by strong endorsement, alongside evolving assessments of transmission dynamics and protective thresholds. Fauci maintained that such adaptations reflected the scientific process amid uncertainty, though detractors argued some guidance lacked rigorous data or prioritized non-scientific factors like resource allocation.[100][101] On March 8, 2020, Fauci stated on 60 Minutes that masks were unnecessary for the general public, recommending them primarily for healthcare workers due to limited evidence of benefit for healthy individuals and concerns over supply shortages for medical personnel. By early April 2020, following CDC updates and growing recognition of asymptomatic spread, Fauci supported cloth masks for public use to reduce transmission, explaining the shift as responsive to new data on aerosol dynamics and presymptomatic cases. Critics highlighted emails revealing Fauci's private skepticism about mask efficacy even after the policy reversal, suggesting initial messaging aimed to prevent hoarding rather than purely scientific grounds.[100][101][102] Fauci's guidance on social distancing similarly drew scrutiny for lacking empirical foundation. The six-foot separation rule, widely enforced in policies affecting schools, businesses, and gatherings, originated from CDC adoption of influenza droplet models rather than COVID-specific studies. In his June 3, 2024, congressional testimony, Fauci conceded the metric "sort of just appeared" without a dedicated discussion or supporting data in his recollection, describing it as an empiric decision amid crisis response. This admission fueled debates over whether the rule, despite its intent to limit close-contact exposure, imposed disproportionate societal costs without proportional evidence of efficacy against airborne spread.[103][104] Assessments of asymptomatic and presymptomatic transmission also evolved, influencing broader mitigation strategies. Early in the pandemic, Fauci and agencies emphasized symptomatic cases, but by June 2020, he estimated 40-45% of infections stemmed from asymptomatic individuals, contradicting a WHO statement and bolstering rationales for universal masking and testing. This update aligned with epidemiological models but contrasted initial underemphasis, contributing to perceptions of reactive rather than proactive guidance.[102][105] Regarding herd immunity, Fauci initially cited 60-70% population immunity as sufficient in mid-2020, adjusting upward to 70-75% by December amid vaccine rollout projections and waning public uptake polls. He later deemed the threshold "elusive" and potentially unattainable due to viral mutations and breakthrough infections, rejecting reliance on natural infections as "nonsense and dangerous" in favor of vaccination-driven protection. These revisions, while reflecting variant emergence, overlooked robust natural immunity data in some models, per critics, and shifted emphasis from absolute thresholds to ongoing vaccination amid persistent transmission.[106][107][108]Allegations of Record Manipulation and Suppression of Dissent
David Morens, a senior advisor to Anthony Fauci at the National Institute of Allergy and Infectious Diseases (NIAID), faced allegations of unlawfully deleting federal records related to COVID-19 origins and using personal email to evade Freedom of Information Act (FOIA) requests, as detailed in emails obtained by the House Select Subcommittee on the Coronavirus Pandemic.[109][110] In one email dated June 28, 2021, Morens wrote to EcoHealth Alliance president Peter Daszak, stating he had "deleted all emails" to avoid FOIA and would "take pains to delete emails with you or Peter," amid scrutiny over NIH funding to the Wuhan Institute of Virology.[109][111] Morens also admitted in emails to collaborating with NIH's FOIA office to hide records, including using personal Gmail for sensitive discussions and misspelling terms to thwart searches, tactics allegedly taught by an NIH FOIA specialist.[112][113] During a May 22, 2024, House subcommittee hearing, Morens invoked the Fifth Amendment over 100 times when questioned about these practices, prompting bipartisan criticism for undermining public trust and NIH operations.[114][115] Fauci's former chief of staff, Greg Folkers, was separately accused of employing similar evasion by misspelling words in communications to avoid FOIA detection.[112] Fauci denied knowledge of or involvement in Morens's actions during his June 3, 2024, congressional testimony, asserting that Morens operated independently and that no records were deleted under his direction.[116][117] Allegations extended to Fauci's potential awareness, with a House subcommittee memo citing emails where Morens referenced Fauci's views on protecting EcoHealth funding and deleting incriminating content to shield Fauci from scrutiny.[109][118] Senator Rand Paul urged a Department of Justice probe into Morens for destroying records and FOIA violations, arguing it impeded investigations into COVID-19 origins.[110] On suppression of dissent, Fauci faced accusations of orchestrating efforts to discredit the COVID-19 lab leak hypothesis, including influencing the March 2020 "Proximal Origin" paper in Nature Medicine, which dismissed engineered virus claims despite initial private concerns from co-authors like Kristian Andersen, who emailed Fauci on January 31, 2020, about SARS-CoV-2 features suggesting possible lab manipulation.[99][119] A House hearing on June 3, 2024, highlighted how Fauci and NIH leaders allegedly worked to label lab leak proponents as conspiracy theorists, despite Fauci later acknowledging in testimony that he never ruled it out as a possibility.[117][119] Critics, including subcommittee Chairman Brad Wenstrup, argued this suppression stifled scientific debate, with emails showing Fauci coordinating teleconferences with virologists to counter lab leak concerns shortly after Andersen's email, contributing to a narrative that marginalized dissenting researchers and delayed origin inquiries.[120][99] Fauci rejected these claims, stating during closed-door interviews and public hearings that he supported investigating all hypotheses equally and did not suppress the lab leak theory, attributing early dismissals to scientific consensus at the time.[121][117] The subcommittee's findings posited that such actions prioritized institutional protection over transparent inquiry, though Fauci maintained they reflected evidence-based assessments rather than censorship.[119]Congressional Investigations and Testimonies
Fauci testified before the House Oversight and Government Reform Committee on March 11, 2020, providing an update on the federal response to COVID-19, emphasizing the need for robust testing and preparedness gaps exposed by the outbreak.[122] He appeared before the Senate Health, Education, Labor, and Pensions (HELP) Committee on May 12, 2020, discussing strategies for safely resuming work and school amid the pandemic, stressing data-driven reopenings and the role of masks and distancing.[123] Additional Senate testimonies followed, including on July 31, 2020, where Fauci, alongside CDC Director Robert Redfield and others, addressed vaccine development progress and ongoing challenges in containment.[124] During Senate HELP Committee hearings in 2021, Fauci faced pointed questioning from Senator Rand Paul on National Institutes of Health (NIH) funding of gain-of-function research. On November 4, 2021, Paul accused Fauci of NIH grants to EcoHealth Alliance supporting experiments at the Wuhan Institute of Virology that enhanced bat coronaviruses' infectivity, citing EcoHealth's reports of viral growth beyond predicted levels.[125] Fauci maintained that such work did not meet the U.S. government’s definition of gain-of-function research of concern, as it involved naturally occurring viruses without deliberate enhancement to increase transmissibility or lethality in humans, though he acknowledged the experiments' proximity to that threshold.[126] Similar exchanges occurred on July 20, 2021, with Paul alleging Fauci's shifting definitions and potential perjury; Fauci rejected the claims, asserting NIH oversight ensured compliance.[127] The House Select Subcommittee on the Coronavirus Pandemic, established in 2023 under Republican leadership, conducted extensive probes into pandemic origins, public health policies, and federal agency roles, with Fauci as a central figure.[128] Fauci provided closed-door transcribed interviews on January 8-9, 2024, spanning 14 hours, where he addressed NIH funding decisions, lab leak hypotheses, and internal communications; a subsequent Republican memo highlighted admissions of bureaucratic inefficiencies and lack of evidence for certain policies.[128] In a public hearing on June 3, 2024, titled "A Hearing with Dr. Anthony Fauci," lawmakers grilled him on suppressing lab leak discussions, funding Wuhan research, and policy rationales.[104] Fauci denied orchestrating censorship, stating he never favored one origin theory but deemed natural zoonosis more likely based on available data; he conceded the six-foot social distancing rule lacked specific scientific backing, originating from WHO models rather than rigorous trials, and affirmed his support for Trump administration travel restrictions from China and Europe.[8] Democrats on the subcommittee defended Fauci's actions as evidence-based amid uncertainty, while Republicans cited emails and documents suggesting efforts to downplay lab-related risks.[116] Investigations revealed no criminal charges against Fauci, though Senator Paul in 2025 renewed referrals to the Department of Justice over alleged record deletions and false statements on gain-of-function, based on FOIA-obtained emails and grant records.[129] Fauci maintained throughout that his testimonies aligned with evolving scientific consensus and NIH protocols, rejecting accusations of misconduct as politically motivated distortions.[130]Post-Retirement Period
Retirement Transition and Financial Disclosures
Anthony Fauci announced his intention to step down from his positions as director of the National Institute of Allergy and Infectious Diseases (NIAID), chief medical advisor to the President, and member of the White House Coronavirus Task Force on August 22, 2022, with the transition effective at the end of December 2022 after over 50 years of continuous government service.[131][132][133] He described the move not as full retirement but as pursuing the "next phase" of his career, amid ongoing congressional scrutiny over COVID-19 policies and funding decisions during his tenure.[134][135] Fauci's federal pension, calculated under the Civil Service Retirement System based on his final salary of approximately $480,654 and 55 years of service, was estimated to exceed $414,000 in the first year, surpassing President Biden's $400,000 salary and marking one of the largest such packages in U.S. federal history, with annual cost-of-living adjustments thereafter.[136][137][138] Financial disclosures released via Freedom of Information Act requests revealed that Fauci's household assets, including investments and real estate, grew by more than $3.5 million in 2023—his first full post-retirement year—to over $15 million total, doubling from early 2019 levels amid the pandemic period.[139][140] Regarding royalties from NIH-licensed inventions, Fauci personally received modest payments—testifying to about $120 monthly from one patent in recent years—contrasting with broader institutional royalties totaling hundreds of millions to NIH entities from pharmaceutical companies, though individual researcher shares are capped at $150,000 annually under federal rules.[141][142] Pre-retirement disclosures for 2020 showed his household income exceeding $1.7 million, incorporating salary, investment gains, and limited royalties, but no detailed post-retirement royalty breakdowns were publicly specified beyond ongoing patent entitlements.[143] Additionally, post-retirement security costs borne by taxpayers reached $15 million through 2024, justified by threats linked to his pandemic role.[144] These disclosures, obtained primarily through watchdog groups like OpenTheBooks, have fueled demands for greater transparency given Fauci's influence over billions in research funding.[145]Publications and Public Engagements
Following his retirement from the National Institute of Allergy and Infectious Diseases (NIAID) on December 31, 2022, Anthony Fauci published his memoir On Call: A Doctor's Journey in Public Service on June 18, 2024, through Viking, an imprint of Penguin Random House.[146] The book chronicles his career spanning over five decades in public health, including responses to HIV/AIDS, Ebola, Zika, and COVID-19, while addressing criticisms of his policy recommendations and emphasizing institutional challenges in pandemic preparedness.[147] Fauci co-authored a commentary titled "Reflection on the Legacy of Lawrence Gostin in Global Health" in the Journal of Law, Medicine & Ethics, published on April 14, 2025, reflecting on Gostin's contributions to public health law amid ongoing debates over emergency powers and international health regulations.[148] Fauci's post-retirement public engagements have primarily focused on promoting his memoir, delivering lectures on public health lessons, and participating in interviews. On February 1, 2025, he engaged in a fireside chat hosted by an unspecified organization, discussing his NIAID tenure from 1984 to 2022 and pandemic decision-making.[149] He delivered a public lecture to approximately 450 attendees at the Agricultural Hall in Martha's Vineyard on July 18, 2025, recounting his service across seven U.S. presidential administrations.[150] His Distinguished Carlson Lecture at the University of Minnesota's Northrop Auditorium, originally scheduled for October 22, 2024, was rescheduled and held on April 8, 2025, where he addressed emerging infectious disease threats.[151] On October 16, 2025, Fauci participated in a virtual discussion titled "Insights from 50 Years of Public Service," drawing on his advisory roles to presidents from Reagan to Biden.[152] These appearances have coincided with financial disclosures revealing his household earned over $3.5 million in 2023, including advances from book deals and speaking fees, prompting scrutiny over post-government income sources.[145]Personal Life
Family and Relationships
Anthony Fauci was born on December 24, 1940, in Brooklyn, New York, to Stephen A. Fauci and Eugenia Abys Fauci, both pharmacists of Italian ancestry who owned and operated a family pharmacy in the Bensonhurst neighborhood.[3] [153] The family resided above the pharmacy, where Fauci assisted during his youth, an experience that influenced his early interest in science and medicine.[154] Fauci met Christine Grady, a nurse and bioethicist, in 1983 while both worked at the National Institutes of Health on AIDS-related patient care.[155] They married in 1985 at Georgetown University's Dahlgren Chapel.[156] [157] Grady, who later headed the NIH Department of Bioethics, balanced her career with family responsibilities alongside Fauci's demanding role.[158] The couple has three daughters: Jennifer, Megan, and Alison, all of whom are adults pursuing independent careers, including one as a clinical psychologist, another as an elementary school teacher, and the third with prior experience at the U.S. State Department.[159] [160] Fauci and Grady prioritized family dinners when possible amid their professional commitments.[161] The family has faced harassment and threats linked to Fauci's public profile, particularly during the COVID-19 pandemic.[162]Lifestyle and Interests
Fauci has described a highly disciplined daily routine dominated by professional demands, waking at 5:10 a.m. for emails and early media appearances, followed by extended work hours that often span seven days a week with minimal breaks beyond meals.[163][164] Physical fitness forms a core element of his lifestyle, with Fauci maintaining a history as a marathon runner and sprinter who participated in 10K races; in his later years, he shifted to nightly power walks, frequently joined by his wife, as a means of stress relief and health preservation.[165][166][167] He advocates nutritional discipline, avoidance of smoking, and moderation in alcohol to support longevity and cognitive sharpness.[168][169] Beyond exercise, Fauci's personal interests remain closely tied to sustaining professional vigor, with no prominent public accounts of pursuits such as literature, music, or recreational sports fandom, though he has engaged in discussions on athletic topics from a public health perspective.[170]Professional Recognition
Organizational Memberships
Fauci has been a member of the National Academy of Sciences since his election in 1992.[171] He was elected to the American Academy of Arts and Sciences in 1991.[172] Fauci joined the National Academy of Medicine, formerly known as the Institute of Medicine, and served on its council.[173] In immunology and infectious diseases professional societies, Fauci has held membership in the American Association of Immunologists since 1973 and was designated a Distinguished Fellow (DFAAI).[174] He is a fellow of the Infectious Diseases Society of America.[175] Fauci was elected to the American Society for Clinical Investigation in 1976.[176] Fauci served as president of the Association of American Physicians in 1999.[177] He is a member of the American College of Physicians.[173] In 2022, he was inducted as an honorary member of Delta Omega, the public health honorary society.[178] Fauci was elected a Foreign Member of the Royal Society (ForMemRS) in recognition of his contributions to immunology.[179]Awards and Honors
Anthony S. Fauci has received more than 120 professional awards and 40 honorary doctoral degrees from institutions in the United States and abroad for his work in immunology, infectious diseases, and public health leadership.[1][180] His highest-profile U.S. government honor is the Presidential Medal of Freedom, the nation's highest civilian award, presented by President George W. Bush on June 19, 2008, recognizing Fauci's role in advancing research and treatments for HIV/AIDS that "brought hope and healing to tens of millions."[181][182] Other significant awards include:| Award | Year | Presented by |
|---|---|---|
| Lasker Award for Clinical Medical Research | 2007 | Lasker Foundation |
| Gustav O. Lienhard Award for Advancement of Health Services | 2020 | National Academy of Medicine |
| Federal Employee of the Year (Service to America Medal) | 2020 | Partnership for Public Service |
| Dan David Prize | 2021 | Dan David Foundation |
| Elliot L. Richardson Prize for Excellence in Public Service | 2022 | R. Duke Stopford Foundation (shared with Francis Collins) |
| Award of Honor | 2021 | American Hospital Association |
| Frank A. Calderone Prize in Public Health | 2023 | Columbia University Mailman School of Public Health |